Market Analysts see Landos Biopharma Inc. [LABP] falling to $1.40. Time to buy?

Landos Biopharma Inc. [NASDAQ: LABP] closed the trading session at $0.33 on 11/02/22. The day’s price range saw the stock hit a low of $0.30, while the highest price level was $0.355. The company report on September 6, 2022 that Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Dr. Cataldi Brings Over Two Decades of Clinical Research and Drug Development Experience in Gastroenterology and Immunology.

The stocks have a year to date performance of -93.09 percent and weekly performance of -7.30 percent. The stock has been moved at -62.33 percent over the last six months. The stock has performed -47.13 percent around the most recent 30 days and changed -70.66 percent over the most recent 3-months.

If compared to the average trading volume of 173.58K shares, LABP reached to a volume of 4490356 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Landos Biopharma Inc. [LABP]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LABP shares is $3.27 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LABP stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Landos Biopharma Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on April 12, 2022. While these analysts kept the previous recommendation, SVB Leerink dropped their target price from $20 to $16. The new note on the price target was released on November 16, 2021, representing the official price target for Landos Biopharma Inc. stock. Previously, the target price had yet another raise to $45, while Craig Hallum analysts kept a Buy rating on LABP stock.

The Average True Range (ATR) for Landos Biopharma Inc. is set at 0.07 The Price to Book ratio for the last quarter was 0.26, with the Price to Cash per share for the same quarter was set at 1.40.

LABP stock trade performance evaluation

Landos Biopharma Inc. [LABP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.30. With this latest performance, LABP shares dropped by -47.13% in over the last four-week period, additionally sinking by -62.33% over the last 6 months – not to mention a drop of -97.62% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LABP stock in for the last two-week period is set at 23.02, with the RSI for the last a single of trading hit 18.42, and the three-weeks RSI is set at 28.12 for Landos Biopharma Inc. [LABP]. The present Moving Average for the last 50 days of trading for this stock 0.6927, while it was recorded at 0.3366 for the last single week of trading, and 1.1770 for the last 200 days.

Landos Biopharma Inc. [LABP]: An insightful look at the core fundamentals

Landos Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.90 and a Current Ratio set at 8.90.

Landos Biopharma Inc. [LABP]: Insider Ownership positions

There are presently around $7 million, or 60.50% of LABP stock, in the hands of institutional investors. The top three institutional holders of LABP stocks are: PERCEPTIVE ADVISORS LLC with ownership of 14,869,915, which is approximately 0% of the company’s market cap and around 24.48% of the total institutional ownership; RTW INVESTMENTS, LP, holding 4,275,722 shares of the stock with an approximate value of $1.42 million in LABP stocks shares; and OUP MANAGEMENT CO., LLC, currently with $0.41 million in LABP stock with ownership of nearly -23.258% of the company’s market capitalization.

Positions in Landos Biopharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 17 institutional holders increased their position in Landos Biopharma Inc. [NASDAQ:LABP] by around 285,648 shares. Additionally, 32 investors decreased positions by around 1,822,020 shares, while 6 investors held positions by with 20,054,999 shares. The mentioned changes placed institutional holdings at 22,162,667 shares, according to the latest SEC report filing. LABP stock had 9 new institutional investments in for a total of 164,430 shares, while 18 institutional investors sold positions of 699,555 shares during the same period.


Please enter your comment!
Please enter your name here